Bio-Rad Laboratories Inc. (BIO)

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.

IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth q...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule ...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of blueb...

Review Bio-Rad's (BIO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Jon DiVincenzo - President...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.90 per share, missing the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $3.10 per share a year ago.